Sanofi Completes Dynavax Acquisition

Sanofi has completed its acquisition of Dynavax Technologies Corporation. The transaction includes Dynavax’s adult hepatitis B vaccine HEPLISAV-B, marketed in the US as a differentiated two-dose regimen over one month.

The deal also brings Dynavax’s shingles vaccine candidate Z-1018, which is in Phase 1/2 studies, along with additional vaccine pipeline projects. Sanofi’s tender offer for all outstanding Dynavax common shares expired on February 9, 2026, and Sanofi accepted and paid for shares validly tendered.

Following acceptance, Sanofi completed the acquisition via a merger under Delaware law, with Dynavax continuing as the surviving corporation and becoming an indirect, wholly owned subsidiary of Sanofi. Dynavax common stock ceased trading on the NASDAQ Global Select Stock Market on February 10, 2026.